home / stock / ikna / ikna quote
Last: | $1.32 |
---|---|
Change Percent: | -2.27% |
Open: | $1.35 |
Close: | $1.32 |
High: | $1.38 |
Low: | $1.3 |
Volume: | 369,054 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.32 | $1.35 | $1.32 | $1.38 | $1.3 | 369,054 | 05-03-2024 |
$1.32 | $1.34 | $1.32 | $1.34 | $1.28 | 319,175 | 05-02-2024 |
$1.3 | $1.34 | $1.3 | $1.35 | $1.285 | 129,322 | 05-01-2024 |
$1.32 | $1.31 | $1.32 | $1.35 | $1.31 | 76,413 | 04-30-2024 |
$1.33 | $1.3 | $1.33 | $1.33 | $1.28 | 149,972 | 04-29-2024 |
$1.3 | $1.3 | $1.3 | $1.3364 | $1.28 | 122,141 | 04-26-2024 |
$1.31 | $1.28 | $1.31 | $1.36 | $1.28 | 138,461 | 04-25-2024 |
$1.29 | $1.39 | $1.29 | $1.39 | $1.27 | 154,016 | 04-24-2024 |
$1.35 | $1.31 | $1.35 | $1.42 | $1.3 | 263,920 | 04-23-2024 |
$1.3 | $1.31 | $1.3 | $1.38 | $1.27 | 239,341 | 04-22-2024 |
$1.33 | $1.25 | $1.33 | $1.33 | $1.25 | 334,007 | 04-19-2024 |
$1.26 | $1.24 | $1.26 | $1.29 | $1.22 | 184,615 | 04-18-2024 |
$1.24 | $1.28 | $1.24 | $1.32 | $1.23 | 173,531 | 04-17-2024 |
$1.27 | $1.27 | $1.27 | $1.3799 | $1.25 | 205,102 | 04-16-2024 |
$1.28 | $1.36 | $1.28 | $1.36 | $1.26 | 190,758 | 04-15-2024 |
$1.33 | $1.39 | $1.33 | $1.39 | $1.31 | 230,102 | 04-12-2024 |
$1.38 | $1.29 | $1.38 | $1.39 | $1.26 | 290,233 | 04-11-2024 |
$1.26 | $1.35 | $1.26 | $1.35 | $1.22 | 241,848 | 04-10-2024 |
$1.33 | $1.32 | $1.33 | $1.38 | $1.3 | 272,175 | 04-09-2024 |
$1.32 | $1.43 | $1.32 | $1.44 | $1.27 | 444,315 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ikena Oncology Inc. Company Name:
IKNA Stock Symbol:
NASDAQ Market:
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new ter...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalati...